Post-Pandemic Planning for Life Sciences Companies

Summary

Avalere’s data analytics and market access experts will be joined by Jeff Patton, MD and CEO of OneOncology, to explore critical issues and considerations for life sciences stakeholders following the pandemic.

Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

Access Recording

Access Webinar Slides

COVID-19 fundamentally changed the way patients experience the healthcare system. As the pandemic wanes, the biopharmaceutical industry will need to adjust its business practices to reflect the post-pandemic landscape and serve patients and customers effectively. In this webinar, Avalere experts will discuss key issues for consideration, including:

Predictive analytics to examine the evolving patient journey and utilization patterns, including telehealth use
Customer engagement strategies, including innovative approaches to segmentation and super customers
Next-generation patient support programs and the needs created by the shifting coverage landscape

Panelists

Moderator

Elizabeth Carpenter , President

As president of Avalere Health, Elizabeth Carpenter is responsible for the firm’s consulting, sales, and operational functions.

Speaker

Lance Grady , Executive Vice President, Life Sciences Strategy & Growth

Lance Grady is the head of Avalere’s Life Sciences Strategy & Growth.

Guest Speaker

Jeffrey F. Patton, M.D. , Chief Executive Officer, OneOncology

Jeff Patton, MD, is a board-certified hematologist and oncologist, Chief Executive Officer and Board of Directors member at OneOncology, where he also served as President of Physician Services for over a year.

Guest Speaker

Nathan Markward , Principal Research Scientist, Health Economics & Advanced Analytics, Avalere Health

Nathan Markward is principal research scientist for Avalere’s Health Economics and Advanced Analytics practice where he leads the conceptualization, execution, and delivery of comparative effectiveness, HEOR, performance improvement, and risk adjustment studies that drive opportunity identification and value creation for a diverse array of clients, including biopharmaceutical companies, device manufacturers, health plans, provider networks, patient advocacy groups, and medical societies.